✦ LIBER ✦

Investigating cognitive consequences of treatment for childhood acute lymphoblastic leukemia

✍ Scribed by Norma Auger; Katherine Patterson Kelly; Amy Bayles; Andrew S. Bradlyn; Patti J. Byron; Karen Kinahan; Debbie Lafond; Ida M. Moore; Callista Roy Sr

Book ID: 117833071
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 169 KB
Volume: 16
Category: Article
ISSN: 0749-2081
DOI: 10.1053/sonu.2000.16585

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Research on cognitive consequences of tr

Research on cognitive consequences of treatment for childhood acute lymphoblastic leukemia

✍ Callista Roy Sr 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Research on cognitive consequences of tr

Research on cognitive consequences of treatment for childhood acute lymphoblastic leukemia

✍ Andrew S. Bradlyn 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Treatment of Childhood Acute Lymphoblast

Treatment of Childhood Acute Lymphoblastic Leukemia

✍ Martin Stanulla; Martin Schrappe 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Incidence of secondary acute myelogenous

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia

✍ Susan G. Kreissman; Richard D. Gelber; Harvey J. Cohen; Luis A. Clavell; Pearl L 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Current concepts in treatment of childho

Current concepts in treatment of childhood acute lymphoblastic leukemia

✍ Ching-Hon Pui 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 411 KB

Results of treatment of high risk childh

Results of treatment of high risk childhood acute lymphoblastic leukemia

✍ Kende, George ;El-Najjar, Khamis ;Ben-Bassat, Isaac ;Neuman, Yoram ;Ballin, Ami 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

Sixteen children with high risk acute lymphoblastic leukemia (ALL) who had one or more of the following risk factors: white cell count over 50 x 10g/liter, mediastinal mass, age under 2 or over 10 years, extramedullary involvement, or T-cell markers, were treated by a new protocol. All attained comp